Drug Profile
SP 20203
Alternative Names: SP-20203Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Sarfez Pharmaceuticals
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Resistant hypertension
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Resistant hypertension in USA (unspecified route) (Sarfez Pharmaceuticals website, September 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Resistant-hypertension in USA
- 08 Dec 2015 Preclinical trials in Resistant hypertension in USA (unspecified route) prior to December 2015